



## Sanofi, IDF and PHFI partner to fight diabetes among children in India

**- KiDS (Kids and Diabetes in Schools) project aims to foster a school environment that creates a better understand of diabetes and support children with this condition –**

**Mumbai, India – September 30, 2013** – Sanofi (EURONEXT: SAN and NYSE: SNY), the International Diabetes Federation (IDF) and Public Health Foundation of India (PHFI) announced today *their first joint public health initiative in India*, KiDS (Kids and Diabetes in Schools). For children with Type 1 diabetes, the project aims to encourage a safe and supportive school environment to manage their diabetes and avoid discrimination. In addition, the program will raise awareness on diabetes (Type 1 and Type 2) and benefits of healthy nutrition and exercise habits among school children.

In India, diabetes is a major public health challenge and the country is today ranked at no. 2 globally. While Type 2 diabetes has received considerable attention in interventions, it has not been so for Juvenile or Type 1 diabetes, even though **1 out of 5 children with Type 1 diabetes in the world would be an Indian.** (ref.: International Diabetes Federation Diabetes Atlas. 5<sup>th</sup> ed. Brussels: IDF; 2011)

If Type 1 diabetes is not detected and diagnosed, it could pose a grave challenge for children and families, who need adequate knowledge and resources for effective management of the condition.

Schools are ideal to raise awareness and train students, teachers and parents about Type 1 diabetes. These days, universal primary education with 'Education for All' as the central theme, is at the forefront of governmental policy, The proposed school based intervention will not just focus on Type 1, but also Type 2 diabetes since the prevalence of obesity is increasing and people are developing Type 2 diabetes at a younger age. This will ensure overall benefit to school children of all age groups and their families.

**Launching the KiDS project at a media conference in Mumbai, Chris Viehbacher, Chief Executive Officer, Sanofi stated** *"As a global leader in diabetes care, we focus on bringing real benefits to people with diabetes, not just providing a comprehensive portfolio of treatments and innovative patient-friendly devices, but also accompanying them in their daily life. With close support, we can really make a difference in patient outcomes so we are very committed to partnering with key stakeholders to create the best patient support programs possible. In India, through our alliance with IDF and PHFI, the KiDS project will help children with Type 1 diabetes fight discrimination and manage their disease better. The project will also include health education for the school children to curb the increasing burden of Type 2 diabetes."*

*"In a developing country like India, barriers to diabetes self-management at school are significant."* said **Sir Michael Hirst, President of IDF.** *"By engaging with policy makers and education authorities, organizing meetings in local communities and providing educational resources to schools, KiDS will raise awareness of diabetes, and the benefits of healthy nutrition and exercise habits among school-age children. IDF is delighted that, in partnership with Sanofi and PHFI, KiDS will bring about a systemic change for children with diabetes in schools."*

**Dr. K Srinath Reddy, President - PHFI** shared that "The program's first step was a feasibility study to understand the status of diabetes management by reviewing current policies on diabetes in schools, existing school guidelines and initiatives, any best practices -- and identify gaps in the knowledge so that appropriate

resources and dissemination routes can be developed. We found that there are no structured training programs, plan or activity, implemented in the school settings that focus on diabetes management. Almost all the respondents emphasized the need for a comprehensive awareness/educational programme in schools to sensitize students, teachers and parents on management of Type 1 diabetes, and control of risk factors for Type 2 diabetes.”

Type 1 diabetes is a challenge especially for school-going children who have to cope with the disease and also face stigma associated with it. They are required to follow a structured self-management plan including lifelong insulin use and blood glucose monitoring, physical activity, and a healthy diet. Therefore, the results and learnings from the KiDS project will not only help support children with Type 1 diabetes but also foster a school environment that creates a better understanding of the condition.

### About KiDS project:

#### **The KiDS project milestones include:**

- **Phase 1 in 2014** -Awareness meetings and activities in schools, with key stakeholders from regional authorities, nurses, teachers, parents and children
- Development and distribution of a school diabetes information pack to help teachers educate children about diabetes
- A Global ‘Diabetes in Schools’ Toolkit for IDF Member Associations to roll out the project, across India and in other parts of the world

#### **Phase 2 -**

- Will seek to continue to work with a multi-stakeholder approach to support the children with diabetes in school and to fight discrimination.

### About Diabetes

Diabetes is a chronic disease that occurs as type 1 diabetes, which is an autoimmune disease characterized by the lack of insulin (the hormone that regulates blood glucose concentrations) production by the pancreas, and Type 2, a metabolic disorder in which there are two main biological defects: a deficient production of insulin and reduced ability of the body to respond to the insulin being produced.

Type 1 and Type 2 diabetes are characterized by an increase in blood glucose concentrations (hyperglycemia). Over time, uncontrolled hyperglycemia leads to the macrovascular and microvascular complications of diabetes. Macrovascular complications, which affect the large blood vessels, include heart attack, stroke and peripheral vascular disease. Microvascular complications affect the small blood vessels of the eyes (retinopathy), kidney (nephropathy) and nerves (neuropathy). The global incidence of diabetes is growing at an alarming rate, with more than 371 million people worldwide living with the condition today.

The International Diabetes Federation has reported that the 63 million diabetic patients in India in 2012 would rise to 101.2 million by 2030<sup>i</sup>. In India, the Type1 burden is estimated at 97,700 children<sup>ii</sup>.

### Challenges of Type 1 diabetes in children

In addition to the rigors of treatment, many children and adolescents find it difficult to cope emotionally with their condition. Diabetes can result in discrimination and may limit social relationships. It may also have an impact on how well a child does in school. The costs of treatment and monitoring equipment combined with the daily needs of a child with diabetes may place a serious financial and emotional burden on the whole family. In many countries, access to self-care tools including self-management education and also to insulin is limited, and this may lead to severe handicap and early death in children with diabetes.

(Adapted from -- <http://www.idf.org/diabetesatlas/5e/diabetes-in-the-young>)

### About Sanofi Diabetes

Sanofi strives to help people manage the complex challenge of diabetes by delivering innovative, integrated and personalized solutions. Driven by valuable insights that come from listening to and engaging with people living with diabetes, the Company is forming partnerships to offer diagnostics, therapies, services and devices, including blood glucose monitoring systems. Sanofi markets both injectable and oral medications for people with Type 1 or Type 2 diabetes.

Aligned to the Sanofi Group's commitment to diabetes, Sanofi Diabetes India strives to become a true 360-degree partner for patients and healthcare professionals, offering a complete range of innovative and integrated solutions.

## About Sanofi

Sanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

## About International Diabetes Federation

The International Diabetes Federation (IDF) is an umbrella organisation of over 200 national diabetes associations in over 160 countries. It represents the interests of the growing number of people with diabetes and those at risk. The Federation has been leading the global diabetes community since 1950. IDF's mission is to promote diabetes care, prevention and a cure worldwide.

## About the Public Health Foundation of India (PHFI)

The Public Health Foundation of India (PHFI) is committed to working towards a healthier India. PHFI is helping to build public health institutional capacity in India, through interdisciplinary and health system connected education and training, policy and programme relevant research, evidence based & equity promoting policy development, people empowering health communication & advocacy for prioritised health causes. Established in 2006 as a public private initiative, PHFI is an independent foundation headquartered in New Delhi and its constituent Indian Institutes of Public Health (IIPH) set up by PHFI have a presence in Hyderabad (Andhra Pradesh), Delhi NCR, Gandhinagar (Gujarat) and Bhubaneswar (Odisha). The Foundation is managed by an empowered governing board comprising senior government officials, eminent Indian and international academic and scientific leaders, civil society representatives and corporate leaders. PHFI's school partner HRIDAY has a network of 300 schools in Delhi and 500 schools in India.

For more information please visit [www.phfi.org](http://www.phfi.org)

### Forward-Looking Statements

*This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2012. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.*

---

## Contacts:

### Sanofi India Media Relations

#### Aparna THOMAS

Senior Director - Communications (South Asia) and Public Affairs (India)  
Tel.: + (91) 22 2827 8169  
[aparna.thomas@sanofi.com](mailto:aparna.thomas@sanofi.com)

### International Diabetes Federation

#### Marie-Hélène Charles

Communications Coordinator  
Tel.: + (32) 2 679 5582  
[MarieHelene.Charles@idf.org](mailto:MarieHelene.Charles@idf.org)

---

<sup>i</sup> <http://www.idf.org/diabetesatlas/5e/Update2012> accessed on 24/09/2013

<sup>ii</sup> Kumar KM, Azad K, Zabeen B, Kalra S. Type 1 diabetes in children: Fighting for a place under the sun. Indian J Endocrinol Metab. 2012 Mar;16 Suppl. 1:S1-3.